Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
- PMID: 17140455
- PMCID: PMC1697823
- DOI: 10.1186/1476-4598-5-67
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Abstract
Background: Recently, a small population of cancer stem cells in adult and pediatric brain tumors has been identified. Some evidence has suggested that CD133 is a marker for a subset of leukemia and glioblastoma cancer stem cells. Especially, CD133 positive cells isolated from human glioblastoma may initiate tumors and represent novel targets for therapeutics. The gene expression and the drug resistance property of CD133 positive cancer stem cells, however, are still unknown.
Results: In this study, by FACS analysis we determined the percentage of CD133 positive cells in three primary cultured cell lines established from glioblastoma patients 10.2%, 69.7% and 27.5%, respectively. We also determined the average mRNA levels of markers associated with neural precursors. For example, CD90, CD44, CXCR4, Nestin, Msi1 and MELK mRNA on CD133 positive cells increased to 15.6, 5.7, 337.8, 21.4, 84 and 1351 times, respectively, compared to autologous CD133 negative cells derived from cell line No. 66. Additionally, CD133 positive cells express higher levels of BCRP1 and MGMT mRNA, as well as higher mRNA levels of genes that inhibit apoptosis. Furthermore, CD133 positive cells were significantly resistant to chemotherapeutic agents including temozolomide, carboplatin, paclitaxel (Taxol) and etoposide (VP16) compared to autologous CD133 negative cells. Finally, CD133 expression was significantly higher in recurrent GBM tissue obtained from five patients as compared to their respective newly diagnosed tumors.
Conclusion: Our study for the first time provided evidence that CD133 positive cancer stem cells display strong capability on tumor's resistance to chemotherapy. This resistance is probably contributed by the CD133 positive cell with higher expression of on BCRP1 and MGMT, as well as the anti-apoptosis protein and inhibitors of apoptosis protein families. Future treatment should target this small population of CD133 positive cancer stem cells in tumors to improve the survival of brain tumor patients.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/1697823/bin/1476-4598-5-67-1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/1697823/bin/1476-4598-5-67-2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/1697823/bin/1476-4598-5-67-3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/1697823/bin/1476-4598-5-67-4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/1697823/bin/1476-4598-5-67-5.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/1697823/bin/1476-4598-5-67-6.gif)
Similar articles
-
CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.Neurosurg Clin N Am. 2012 Jul;23(3):391-405. doi: 10.1016/j.nec.2012.04.011. Epub 2012 Jun 5. Neurosurg Clin N Am. 2012. PMID: 22748652 Review.
-
Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells.Brain Res. 2010 Jun 8;1336:103-11. doi: 10.1016/j.brainres.2010.04.005. Epub 2010 Apr 11. Brain Res. 2010. PMID: 20388502
-
Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma.Cancer Invest. 2009 Nov;27(9):901-8. doi: 10.3109/07357900801946679. Cancer Invest. 2009. PMID: 19832037
-
Expression of multidrug resistance genes in normal and cancer stem cells.Cancer Invest. 2008 Jun;26(5):535-42. doi: 10.1080/07357900801904140. Cancer Invest. 2008. PMID: 18568776
-
Cancer stem cells and brain tumors.Clin Transl Oncol. 2008 May;10(5):262-7. doi: 10.1007/s12094-008-0195-8. Clin Transl Oncol. 2008. PMID: 18490242 Review.
Cited by
-
Biosensor-Enhanced Organ-on-a-Chip Models for Investigating Glioblastoma Tumor Microenvironment Dynamics.Sensors (Basel). 2024 Apr 30;24(9):2865. doi: 10.3390/s24092865. Sensors (Basel). 2024. PMID: 38732975 Free PMC article. Review.
-
The Potential of the Fibronectin Inhibitor Arg-Gly-Asp-Ser in the Development of Therapies for Glioblastoma.Int J Mol Sci. 2024 Apr 30;25(9):4910. doi: 10.3390/ijms25094910. Int J Mol Sci. 2024. PMID: 38732135 Free PMC article.
-
Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.Cancers (Basel). 2024 Mar 25;16(7):1276. doi: 10.3390/cancers16071276. Cancers (Basel). 2024. PMID: 38610954 Free PMC article. Review.
-
vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target.Antibodies (Basel). 2024 Mar 18;13(1):25. doi: 10.3390/antib13010025. Antibodies (Basel). 2024. PMID: 38534215 Free PMC article. Review.
-
Cancer Stem Cells: Current Challenges and Future Perspectives.Methods Mol Biol. 2024;2777:1-18. doi: 10.1007/978-1-0716-3730-2_1. Methods Mol Biol. 2024. PMID: 38478332 Review.
References
-
- Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–5828. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous